Compare McKesson Corporation (MCK) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Otis Worldwide Corp — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while Otis Worldwide Corp trades at $65.95 (market cap $25.17B). The key difference: McKesson Corporation is far larger — about 4.3× Otis Worldwide Corp's market cap, and Otis Worldwide Corp pays the higher dividend (2.66%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Otis Worldwide Corp for 66 Days on average.
| MCK | OTIS | |
|---|---|---|
Market Cap | $108.46B | $25.17B |
Volume | 712,607 | 4,542,442 |
Sector | Health | Industrials |
52-Week High | $995.69 | $93.62 |
52-Week Low | $725.17 | $64.05 |
Typical Hold Time | 74 Days | 66 Days |
Enterprise Value | $115.00B | $33.20B |
Dividend Yield | 0.4% | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
Otis Worldwide trades at $66.11, near its 52-week low, with a bearish technical signal and recent earnings misses in Q4 2025, Q1 2026, and Q2 2026. The company maintains stable revenue around $14.4B in 2025 but faces margin pressure, with net income margin at 10.17%. Analyst consensus is split between Buy and Hold, with a price target of $87.00, indicating potential upside. Recent news highlights CEO succession plans and challenges in China demand.
The outlook for Otis hinges on service margin recovery and China market stabilization. Investment opportunities include its dominant market position and durable cash flow from service contracts, but risks involve persistent cost pressures, high debt levels, and weak equipment demand. Wall Street remains cautiously optimistic given the valuation discount to targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
